Polysaccharide aerogels have emerged as a highly promising technology in the field of oral drug delivery. These nanoporous, ultralight materials, derived from natural polysaccharides such as cellulose, starch, or chitin, have significant potential in colonic drug delivery due to their unique properties. The particular degradability of polysaccharide-based materials by the colonic microbiota makes them attractive to produce systems to load, protect, and release drugs in a controlled manner, with the capability to precisely target the colon. This would allow the local treatment of gastrointestinal pathologies such as colon cancer or inflammatory bowel diseases. Despite their great potential, these applications of polysaccharide aerogels have not been widely explored. This review aims to consolidate the available knowledge on the use of polysaccharides for oral drug delivery and their performance, the production methods for polysaccharide-based aerogels, the drug loading possibilities, and the capacity of these nanostructured systems to target colonic regions.
5 December 2024 in International Journal of Pharmaceutics
Current protein-based therapies often rely on intravenous and subcutaneous injections leading to patient discomfort due to the need for frequent administration. Oral administration route presents a more patient-friendly alternative, but overcoming the challenge of low drug bioavailability remains paramount. This limitation is primarily attributed to protein degradation in the harsh gastric environment, enzymatic breakdown, and poor intestinal permeability. With their unique properties, such as high porosity and surface area, and easy scalability, aerogels offer a promising platform for oral delivery of therapeutic proteins. This study focused on the development and characterization of both conventional and core-shell aerogels derived from natural polysaccharides for the oral delivery of insulin, utilizing Humulin R® U-100 as the insulin source for the first time. Aerogels were produced via supercritical carbon dioxide (sc-CO2) drying of alginate gel beads. Scanning Electron Microscopy (SEM) images confirmed that the core-shell aerogels had higher uniformity in size and a more well-defined porous structure in comparison to conventional aerogels. Structural differences of two alginate sources were evaluated by Fourier Transform Infrared (FTIR) spectroscopy. A notable difference in encapsulation efficiencies was observed between conventional (12 %) and core-shell (53 %) aerogels, highlighting the superior carrier characteristics of the latter ones. In vitro insulin release profiles from the core-shell aerogels demonstrated their potential suitability for delivering regular/short-acting insulin therapeutics since only 30 % of insulin was released in Simulated Gastric Fluid (SGF) after 120 min, whereas 60 % of insulin was released in Simulated Intestinal Fluid (SIF) within the first hour followed by a sustained release stage.
This study explores novel alginate–konjac glucomannan core–shell aerogel particles for drug delivery systems fabricated via air-assisted coaxial prilling. A systematic approach is needed for the optimization of this method due to the numerous processing variables involved. This study investigated the influence of six variables: alginate and konjac glucomannan concentrations, compressed airflow, liquid pump pressures, and nozzle configuration. A hybrid software using Artificial Neural Networks and genetic algorithms was used to model and optimize the hydrogel formation, achieving a 100% desirable solution. The optimal formulation identified resulted in particles displaying a log-normal size distribution (R2 = 0.967) with an average diameter of 1.57 mm. Supercritical CO2 drying yielded aerogels with macropores and mesopores and a high specific surface area (201 ± 10 m2/g). The loading of vancomycin hydrochloride (Van) or a dexamethasone base (DX) into the aerogel cores during the process was tested. The aerogels exhibited appropriate structural characteristics, and both drugs showed burst release profiles with ca. 80% release within 10 min for DX and medium-dependent release for Van. This study demonstrates the feasibility of producing konjac aerogel particles for delivery systems and the high potential of AI-driven optimization methods, highlighting the need for coating modifications to achieve the desired release profiles.
A newly produced silk fibroin (SF) aerogel particulate system using a supercritical carbon dioxide (scCO2)-assisted drying technology is herein proposed for biomedical applications. Different concentrations of silk fibroin (3%, 5%, and 7% (w/v)) were explored to investigate the potential of this technology to produce size- and porosity-controlled particles. Laser diffraction, helium pycnometry, nitrogen adsorption–desorption analysis and Fourier Transform Infrared with Attenuated Total Reflectance (FTIR-ATR) spectroscopy were performed to characterize the physicochemical properties of the material. The enzymatic degradation profile of the SF aerogel particles was evaluated by immersion in protease XIV solution, and the biological properties by cell viability and cell proliferation assays. The obtained aerogel particles were mesoporous with high and concentration dependent specific surface area (203–326 m2/g). They displayed significant antioxidant activity and sustained degradation in the presence of protease XIV enzyme. The in vitro assessment using human dermal fibroblasts (HDF) confirm the particles’ biocompatibility, as well as the enhancement in cell viability and proliferation.